Clinical trials: Intestinal Obstruction
- Condition Intestinal Obstruction
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Intestinal Pseudo-obstruction
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
This is a phase II, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of velusetrag once a day, compared to placebo, in subjects with CIPO.
- Trial name
- NCT05724069
- Testing
- Velusetrag 15 mg once daily for 4 weeks.
- Where
- 4 sites in Belgium, Italy and 1 more
- Volunteers
- 17 people
- Sponsor
- Alfasigma S.p.A.
Intestinal Obstruction
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable…
- Trial name
- QoL in IMBO (NCT02365584)
- Testing
- lanreotide (Autogel formulation)
- Where
- 13 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Ipsen
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Intestinal Obstruction
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
To assess the efficacy of Lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube (NGT) and to assess the efficacy of lanreotide Autogel 120 mg…
- Trial name
- IMIO (NCT02275338)
- Testing
- Lanreotide Autogel
- Where
- 17 sites in Belgium
- Volunteers
- 52 people
- Sponsor
- Ipsen
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total…
- Trial name
- IMPROVE-Lap (NCT02058290)
- Testing
- IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL therefore possibly…
- Trial name
- IMPROVE-Open (NCT01507220)
- Testing
- morphine sulfate, bupivacaine liposome extended-release injectable suspension
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly…
- Trial name
- IMPROVE-Open (NCT01507233)
- Testing
- IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Bowel Obstruction
Adult Patients Undergoing Open Colectomy MA402S23B303
This study is designed to compare the standard of care against EXPAREL(R) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
- Trial name
- IMPROVE-Open (NCT01507246)
- Testing
- IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Peritoneal Neoplasms, Intestinal Obstruction
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with…
- Conditions
- Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
- Trial name
- NCT00332696
- Testing
- Octreotide LAR, Octreotide (Immediate release), methylprednisolone
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals